Dibenz[a,h]anthracene

CASRN 53-70-3

  • IRIS Summary (PDF) (12 pp, 114 K)
  • Status: Dibenz[a,h]anthracene is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (12 pp, 114 K)
Not assessed under the IRIS Program.

Reference Concentration for Inhalation Exposure (RfC) (PDF) (12 pp, 114 K)
Not assessed under the IRIS Program.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (12 pp, 114 K) last updated: 12/01/1990

WOE Characterization Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Based on no human data and sufficient data from animal bioassays. Dibenz[a,h]anthracene produced carcinomas in mice following oral or dermal exposure and injection site tumors in several species following subcutaneous or intramuscular administration. Dibenz[a,h]anthracene has induced DNA damage and gene mutations in bacteria as well as gene mutations and transformation in several types of mammalian cell cultures.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (12 pp, 114 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (12 pp, 114 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.